Świderska, J.; Kozłowski, M.; Nowak, K.; Rychlicka, M.; Branecka-Woźniak, D.; Kwiatkowski, S.; Pius-Sadowska, E.; Machaliński, B.; Cymbaluk-Płoska, A.
Clinical Relevance of Soluble Forms of Immune Checkpoint Molecules sPD-1, sPD-L1, and sCTLA-4 in the Diagnosis and Prognosis of Ovarian Cancer. Diagnostics 2022, 12, 189.
https://doi.org/10.3390/diagnostics12010189
AMA Style
Świderska J, Kozłowski M, Nowak K, Rychlicka M, Branecka-Woźniak D, Kwiatkowski S, Pius-Sadowska E, Machaliński B, Cymbaluk-Płoska A.
Clinical Relevance of Soluble Forms of Immune Checkpoint Molecules sPD-1, sPD-L1, and sCTLA-4 in the Diagnosis and Prognosis of Ovarian Cancer. Diagnostics. 2022; 12(1):189.
https://doi.org/10.3390/diagnostics12010189
Chicago/Turabian Style
Świderska, Janina, Mateusz Kozłowski, Katarzyna Nowak, Małgorzata Rychlicka, Dorota Branecka-Woźniak, Sebastian Kwiatkowski, Ewa Pius-Sadowska, Bogusław Machaliński, and Aneta Cymbaluk-Płoska.
2022. "Clinical Relevance of Soluble Forms of Immune Checkpoint Molecules sPD-1, sPD-L1, and sCTLA-4 in the Diagnosis and Prognosis of Ovarian Cancer" Diagnostics 12, no. 1: 189.
https://doi.org/10.3390/diagnostics12010189
APA Style
Świderska, J., Kozłowski, M., Nowak, K., Rychlicka, M., Branecka-Woźniak, D., Kwiatkowski, S., Pius-Sadowska, E., Machaliński, B., & Cymbaluk-Płoska, A.
(2022). Clinical Relevance of Soluble Forms of Immune Checkpoint Molecules sPD-1, sPD-L1, and sCTLA-4 in the Diagnosis and Prognosis of Ovarian Cancer. Diagnostics, 12(1), 189.
https://doi.org/10.3390/diagnostics12010189
